Dermatology Deal Benchmarks
Atopic dermatitis, psoriasis, vitiligo, and alopecia deal benchmarks. Benchmarks derived from 55 verified transactions.
55
Total Deals
$467M
Avg Upfront
4
Deal Types
100%
Terms Disclosed
Deal Structure Distribution
28
license
23
acquisition
2
collaboration
2
option
0
co development
Recent Deals with Disclosed Terms
| Parties | Type | Upfront | Total Value | Date |
|---|---|---|---|---|
Replay → Leo Pharma skin disease gene therapy | license | $50M | — | Apr 2026 |
Boehringer Ingelheim → AbbVie BI 655066 | license | $595M | — | Mar 2026 |
Teva Pharmaceuticals → Royalty Pharma TEV-53408 | license | $75M | $500M | Jan 2026 |
Acera Surgical → Solventum wound care products | acquisition | $725M | $850M | Nov 2025 |
Biofrontera AG, Biofrontera Pharma GmbH and Biofrontera Bioscience GmbH → Biofrontera Inc. Ameluz | acquisition | $4M | — | Jul 2025 |
Concert Pharmaceuticals → Sun Pharmaceutical deuterated JAK inhibitor | acquisition | $576M | $576M | Jun 2025 |
Protagonist Therapeutics → J&J psoriasis | acquisition | $1.0B | $1.0B | Dec 2024 |
Nimble Therapeutics → AbbVie psoriasis | acquisition | $200M | $200M | Oct 2024 |
Numab Therapeutics → Johnson & Johnson atopic_dermatitis | acquisition | $1.3B | $1.3B | Sep 2024 |
Escient Pharmaceuticals → Incyte EP262 and MRGPRX programs | acquisition | $200M | $1.0B | Jul 2024 |
Benchmark Your Dermatology Deal
Get instant benchmarks for upfront payments, milestones, and royalties based on 55 verified dermatology transactions.
Run Dermatology Benchmark